Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
33.33
-0.38 (-1.13%)
At close: Apr 28, 2026, 4:00 PM EDT
34.38
+1.05 (3.15%)
After-hours: Apr 28, 2026, 6:30 PM EDT

Stoke Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2017
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2017
Revenue
184.4236.568.7812.41-
Upgrade
Revenue Growth (YoY)
404.50%316.34%-29.22%--
Upgrade
Gross Profit
184.4236.568.7812.41-
Upgrade
Selling, General & Admin
67.0948.7941.3238.9231.9
Upgrade
Research & Development
137.9289.1382.2377.8454.17
Upgrade
Operating Expenses
205.01137.93123.55116.7686.07
Upgrade
Operating Income
-20.59-101.37-114.77-104.36-86.07
Upgrade
Interest Expense
-0.01-0.03-0.05--
Upgrade
Interest & Investment Income
13.7712.669.963.120.12
Upgrade
Other Non Operating Income (Expenses)
-0.05-0.250.170.170.14
Upgrade
Pretax Income
-6.89-88.98-104.7-101.07-85.81
Upgrade
Net Income
-6.89-88.98-104.7-101.07-85.81
Upgrade
Net Income to Common
-6.89-88.98-104.7-101.07-85.81
Upgrade
Shares Outstanding (Basic)
5954443937
Upgrade
Shares Outstanding (Diluted)
5954443937
Upgrade
Shares Change (YoY)
9.65%22.76%13.11%5.87%9.71%
Upgrade
EPS (Basic)
-0.12-1.65-2.38-2.60-2.34
Upgrade
EPS (Diluted)
-0.12-1.65-2.38-2.60-2.34
Upgrade
Free Cash Flow
44.92-87.05-82.68-35.83-68.11
Upgrade
Free Cash Flow Per Share
0.76-1.61-1.88-0.92-1.85
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%-
Upgrade
Operating Margin
-11.16%-277.31%-1307.21%-841.24%-
Upgrade
Profit Margin
-3.73%-243.42%-1192.47%-814.73%-
Upgrade
Free Cash Flow Margin
24.36%-238.15%-941.72%-288.82%-
Upgrade
EBITDA
-18.82-99.2-112.3-102.81-85.09
Upgrade
EBITDA Margin
-10.21%-271.36%---
Upgrade
D&A For EBITDA
1.772.182.471.550.97
Upgrade
EBIT
-20.59-101.37-114.77-104.36-86.07
Upgrade
EBIT Margin
-11.16%-277.31%---
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.